key: cord-0957614-hnbxfbeo
authors: Lou, Bin; Li, Ting-Dong; Zheng, Shu-Fa; Su, Ying-Ying; Li, Zhi-Yong; Liu, Wei; Yu, Fei; Ge, Sheng-Xiang; Zou, Qian-Da; Yuan, Quan; Lin, Sha; Hong, Cong-Ming; Yao, Xiang-Yang; Zhang, Xue-Jie; Wu, Ding-Hui; Zhou, Guo-Liang; Hou, Wang-Heng; Li, Ting-Ting; Zhang, Ya-Li; Zhang, Shi-Yin; Fan, Jian; Zhang, Jun; Xia, Ning-Shao; Chen, Yu
title: Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset
date: 2020-05-19
journal: Eur Respir J
DOI: 10.1183/13993003.00763-2020
sha: fb06b61cbd6bf279d06fb5cc4d88ad0bba083ea1
doc_id: 957614
cord_uid: hnbxfbeo

BACKGROUND: Timely diagnosis of SARS-CoV-2 infection is a prerequisite for treatment and prevention. The serology characteristics and complement diagnosis value of the antibody test to RNA test need to be demonstrated. METHOD: Serial sera of 80 patients with PCR-confirmed COVID-19 were collected at the First Affiliated Hospital of Zhejiang University, China. Total antibody (Ab), IgM and IgG antibodies against SARS-CoV-2 were detected, and the antibody dynamics during the infection were described. RESULTS: The seroconversion rates for Ab, IgM and IgG were 98.8%, 93.8% and 93.8%, respectively. The first detectible serology marker was Ab, followed by IgM and IgG, with a median seroconversion time of 15, 18 and 20 days post exposure (d.p.e) or 9, 10 and 12 days post onset (d.p.o), respectively. The antibody levels increased rapidly beginning at 6 d.p.o. and were accompanied by a decline in viral load. For patients in the early stage of illness (0–7 d.p.o), Ab showed the highest sensitivity (64.1%) compared to IgM and IgG (33.3% for both, p<0.001). The sensitivities of Ab, IgM and IgG increased to 100%, 96.7% and 93.3% 2 weeks later, respectively. When the same antibody type was detected, no significant difference was observed between enzyme-linked immunosorbent assays and other forms of immunoassays. CONCLUSIONS: A typical acute antibody response is induced during SARS-CoV-2 infection. Serology testing provides an important complement to RNA testing in the later stages of illness for pathogenic specific diagnosis and helpful information to evaluate the adapted immunity status of patients.

In early December 2019, a novel coronavirus (SARS-CoV-2) was first reported to cause lethal pneumonia in humans, and person-to-person transmission was demonstrated soon in Wuhan, the capital city of Hubei Province, China. [1] The virus rapidly spread through China and then many other countries globally. Through May 6, 2020, the virus resulted in over 3.5 million laboratory-confirmed cases of coronavirus disease 2019 (COVID-19) and more than 243,000 deaths in 215 countries.

[2] The World Health Organization (WHO) has declared COVID-19 a public health emergency of international concern and given a "very high" risk assessment on a global level. [3] A recent report from China showed that the median incubation period of COVID-19 infection was 4 days (interquartile range, 2 to 7). [4] Fever, cough and fatigue are the most common symptoms. [1] Severe cases could rapidly progress to acute respiratory distress syndrome (ARDS) and septic shock. Abnormalities on chest computed tomography, particularly ground-glass opacity and bilateral patchy shadowing, were found in over 80% of patients. [5] Over 80% of patients had lymphopenia, and approximately 60% of patients had elevated C-reactive protein. [6] However, the clinical and laboratory findings of COVID-19 infection are not distinguishable from pneumonia caused by infection of some common respiratory tract pathogens, such as influenza virus, Streptococcus pneumoniae and Mycoplasma pneumoniae. [7] Hence, the timely diagnosis of SARS-CoV-2 infection is important for providing appropriate medical support and for preventing the spread by quarantining.

Currently, the diagnosis of SARS-CoV-2 infection almost solely depends on the detection of viral RNA using polymerase chain reaction (PCR)-based techniques. [8] Unfortunately, the sensitivity of the RNA test in the real world is not satisfactory, particularly when samples collected from the upper respiratory tract are used. [9] [10] [11] [12] In Wuhan, the overall positive rate of RNA testing is estimated to be approximately 30-50% in patients with COVID-19 when they come to the hospital.

[13] Furthermore, the overall throughput of available RNA tests is highly limited by their nature of requiring high workload, needing skilful operators for testing and sample collection, and needing costly instruments and special operation places. [14] As a result, convenient serological detection is expected to be helpful. However, current knowledge of the antibody response to SAR-CoV-2 infection is very limited. The diagnostic value of the antibody test remains to be clearly demonstrated. How many patients would raise an antibody response, and how long will it take for the antibody to convert to positive since the exposure? Are there any meaningful differences between patients with short and long incubation periods? What are the sensitivities of antibody detection for patients in different illness stages? Is there any temporal association between the antibody response and the decline in viral load? To answer some of these questions, we investigated the characteristics of antibody responses in 80 patients with COVID-19 during their hospitalization periods by detecting total antibodies, IgM and IgG using immunoassays.

A confirmed COVID-19 case was defined based on the New Coronavirus Pneumonia Prevention and Control Program (6th edition) published by the National Health Commission of China. [15] Briefly, a confirmed case should meet three criteria: 1) fever and/or respiratory symptoms; 2) abnormal lung imaging findings; and 3) positive result of the nucleic acid of SARS-CoV-2. The degree of severity of the patient was categorized as critical if any of the following clinical findings appeared: 1) ARDS or oxygen saturation < 93% and requiring mechanical ventilation either invasively or noninvasively; 2) shock; and 3) complications of organ functional failure and requiring intensive care unit support. A COVID-19 patient who did not meet the above criteria was defined as a non-critical case.

This study enrolled a total of 80 cases of COVID-19, where all patients were admitted to the hospital between Jan 19 and Feb 9, 2020, and were willing to donate their blood samples. All enrolled cases were confirmed to be infected by SARS-CoV-2 through quantitative real-time RT-PCR (qRT-PCR) testing. The date of illness onset, clinical classification, RNA testing results during the hospitalization period, and personal demographic information were obtained from the clinical records. A total of 300 healthy people were enrolled from the local community during the circulation of the virus. All the controls had not reported close contact with any confirmed COVID-19 patient. This study was reviewed and approved by the Medical Ethics Committee of the First Affiliated Hospital of Zhejiang University (approval number 2020-IIT-47).

Written informed consent was obtained from each enrolled subject.

For each patient, sputum specimen was collected preferentially. While sputum was not produced, saliva after deep cough was collected as previously reported [16] . The 

The total antibody (Ab), IgM antibody and IgG antibody against SARS-CoV-2 in plasma samples were tested using three enzyme-linked immunosorbent assays 

The incubation period was defined as the interval between the earliest date of SARS-CoV-2 exposure and the earliest date of symptom onset. Non-normally distributed continuous data were described as the median with interquartile range (IQR) and compared by the Wilcoxon test. Categorical data were summarized as counts and percentages. The 95% confidence intervals of sensitivity and specificity were estimated by binomial exact test. Categorical data were compared using the χ 2 test or Fisher's exact test for unpaired proportions and McNemar's test for paired

proportions. Cumulative seroconversion rates were calculated by the Kaplan-Meier method. All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA).

No patients were involved in setting the research question or the outcome measures, nor were they involved in the design and implementation of the study.

Dissemination to these groups is not possible/applicable.

Among 81 cases of COVID-19 patients admitted to the hospital (before Feb 9, 2020), 80 (99%) patients were enrolled in the study ( Table 1 ). The median age of the patients was 55 years (IQR, 45-64 years), and 38.7% were females. The critical patients were significantly older than the non-critical patients (p<0.001). The time of SARS-CoV-2 exposure before onset in 45 patients (15 were critical cases) was determined according to unambiguous close contact with confirmed patients with COVID-19 through epidemiological inspection upon admission to the hospital. The incubation period ranged from 0 to 23 days with a median of 5 days (IQR, 2 -10 days). By February 15, a total of 32 patients (40%, all were non-critical cases) were recovered and discharged from the hospital, and none died.

A total of 80 patients with COVID-19 and 100 to 300 healthy people were tested for antibodies against SARS-CoV-2 using different immunoassays. The seroconversion rates for Ab, IgM and IgG in patients were 98.8% (79/80), 93.8% (75/80) and 93.8%

(75/80), respectively ( Table 2, the exposure were assigned to the short incubation period group, and the remaining patients were assigned to the long incubation period group (Table 4 ). There was no significant difference in age, viral load in the early stage of illness or the risk of critical status between the groups. However, the median seroconversion time was shorter for the short incubation period group than for the long incubation period group (13 d.p.e vs. 21 d.p.e, p<0.001). In contrast, the median seroconversion days post onset was longer for the short incubation period group than the long incubation period group (10 d.p.o vs. 7 d.p.o, p<0.05).

The present study showed that nearly all (98.8%, 79/80) patients with COVID-19 converted to be seropositive during the illness course. Seroconversion was first observed on 7 d.p.e. The first detectible antibody was total antibody, followed by IgM Currently, the quarantine period is set as 14 days since close contact with a confirmed SARS-CoV-2 infection case. The proportion of infection that could not be screened out through RNA testing during the quarantine period remains unknown. However, it has been documented that some close contactors present symptoms and cause transmission after de-isolation. [19] It is believed that the antibody test might improve the sensitivity to detect infections, but the evidence had not been shown before. Our data showed that the cumulative seroconversion rate was 45.5% on 14 d.p.e. This Recently, Guan et al. [4] reported that the median time from the onset of symptoms to needing mechanical ventilator support is 9.3 days. Therefore, timely diagnosis and admission to the hospital within 7 d.p.o might be crucial to lower the fatality of COVID-19 infection. Zhao et al. [21] reported that the overall RNA positive rate was lower than 70% in patients in the first week post symptom onset and fell to 50% in the next week. Several reports indicated that many patients were finally diagnosed by RNA testing through daily repeat sampling and testing, and many cases that were strongly epidemiologically linked to SARS-CoV-2 exposure and with typical lung radiological findings remained RNA negative. [7] In our study, the RNA positive rate was 100% when admitted to the hospital, but it cannot be excluded that some patients were not diagnosed due to their undetectable viral RNA. Another reason for the relatively high RNA positive rate in our study is that we used a deep sputum sample for RNA testing, in contrast to the more convenient and popular throat/nasal swabs in many other hospitals. This suggests that lower respiratory samples, such as deep sputum and bronchoalveolar lavage, might be more reliable for SARS-CoV-2 RNA detection.

Similar to the RNA test, the negative antibody finding in the early stage of illness could not exclude the possibility of infection. Our study showed that the seroconversion rate on 7 d.p.o reached 64.1% and then increased to over 90% in the next week. The relatively long window period of seroconversion indicates that, for searching previously exposed patients or subclinical carriers, the specific serology should not replace RNA detection but could be an important complement. Furthermore, the fact that nearly all patients will convert to antibody positive and that the titre increased rapidly underlines the usage of antibody tests in confirming or excluding the diagnosis of SARS-CoV-2 infection if the convalescent sample was tested.

The present data showed that the sensitivity of total antibody detection was higher than that of IgM and IgG (p<0.001), while the specificities were overall comparable when the same testing technique (ELISA, CLMA or LFIA) was used. The detection of total antibody is based on double-antigen sandwich methodology. It can detect any type of antibody, including IgM, IgG and IgA, in principle. In addition, the two Fab arms of the same antibody molecule need to bind to the coated antigen and the enzyme-conjugated antigen, which guarantees the specificity of the test and then allows a high concentration of antigens to be used for coating and second binding to increase the sensitivity of the assay. Therefore, it is not unexpected that the sensitivity of total antibody detection is superior to that of IgM and IgG detection in our study. that the total antibody testing by the same Wantai SARS-CoV-2 Ab ELISA as the present study outperformed the assays detecting specific IgG or IgA only in sensitivity and specificity. [22] A Hong Kong group also reported that antibody seroconversion occurred around 10 days after onset, and the patients showed lower viral load in seroconverted stages than earlier. [23] Interestingly, in their study more patients had earlier seroconversion for IgG than IgM. We noted that the indirect ELISA methodology was applied for IgG and IgM antibody detection in their study, despite the μ-chain capture methodology is preferred for IgM testing. Thus it might be explained by the different analytical sensitivity between the assays for detection IgG and IgM.

In our study, antibody tests based on ELISA, CMIA and LFIA were validated and showed good performance overall. CMIA has the advantages of automatic operation and being rapid, high-throughput, objective and quantitative, but it requires a costly specific instrument. ELISA is low-cost, objective and high-throughput and is widely used in most medical laboratories worldwide. LFIA is a rapid point-of-care test that does not require special instrumentation is very convenient and is easy to operate, but the reading of the results is subjective. The establishment of different immunoassays provides flexible choices for users.

Up to date, several reports on antibody response to SARS-CoV-2 infection post illness onset had been published. [21] [22] [23] [24] [25] Although the profiles of antibody response presented in these reports are generally the same, the orders of IgM and IgG seroconversion reported are conflicting. This is possible because of differences in the sensitivity of the assays used in these studies.

The limitations of the study include the following: 1) only symptomatic infections were enrolled; therefore, whether the antibody response to asymptomatic infection follows similar features remains to be determined; 2) most blood samples were collected at one month post onset, so the duration of antibodies cannot be estimated; 3) the antibody levels were not exactly titrated, and different antigens were used in total antibody (RBD), IgM (RBD) and IgG (Nucleoprotein), hence the correlation of the degree of antibody response with clinical severity is not investigated; and 4) no blood sample was collected during the incubation period, and that the serological status before onset was artificially assigned to be negative might overestimate the needing time for seroconversion. Future studies are needed to better understand the antibody response profile of SARS-CoV-2 infection and to precisely interpret the clinical meaning of serology findings.

In conclusion, a typical acute antibody response is induced during SARS-CoV-2 infection. Serology testing provides an important complement to RNA testing for pathogenic specific diagnosis and helpful information to evaluate the adapted immunity status of patients. It should be strongly recommended that well-validated antibody tests be applied in clinical management and public health practice to improve the control of COVID-19 infection. LFIA, lateral flow immunoassay. The combined sensitivities were calculated based on positive findings by any of the assays, and the combined specificities were calculated based on negative findings for all assays. # All the controls had not reported close contact with any confirmed COVID-19 patient, and individuals who showed positive for any of the antibody tests were tested to be PCR negative with sputum or saliva samples collected later. Considered the very limited local community spread of the virus during the period, and for more rigorous evaluation of assay's specificity, the community controls with positive result in antibody assays were considered as false positive. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report -51

China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang

Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China

Laboratory testing of human suspected cases of novel coronavirus (nCoV) infection. Interim guidance v1 ed. World Health Organization

Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China

Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections

Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2) infected pneumonia (COVID-19)

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Recent advances and perspectives of nucleic acid detection for coronavirus

National Health Commission of China New coronavirus pneumonia prevention and control program

Consistent Detection of 2019 Novel Coronavirus in Saliva

Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus

Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Evaluation of nine commercial SARS-CoV-2 immunoassays

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

The procedures for ELISA and CMIA detection.The measurement processes of ELISA and CMIA were conducted with an automatic ELISA analyser HB-300E (Jiaxing CRED Medical Equipment Co. Ltd., China) and automatic CMIA analyser Caris 200 (Xiamen UMIC Medical Instrument Co. Ltd., China) according to the manufacturer's instructions, respectively. In brief, 100 μL of plasma sample was used for ELISA-Ab, and 10 μL of sample was added to 100 μL of sample diluent buffer for ELISA-IgM. For ELISA-IgG, the sample was 20-fold diluted with phosphate buffer, pH7.0, and 10μL of dilution was added to 100 μL sample diluent buffers. Then, the microplates were incubated at 37 ℃ for 30 min and washed for 5 times with washing buffer, followed by addition of 100 μl of enzyme reagent. After incubation at 37℃ for 30 min, the microplates were washed with washing buffer for 5 times again, and 100 μL TMB substrate was added and incubated at 37 ℃ for 15 min. Then, the reaction was terminated by addition of 50 μL 2 M H2SO4 and the optical density at 450 nm with 630 nm as reference (OD450/630) was detected. The cut-off values of ELISA-Ab and ELISA-IgG was determined by mean OD value of negative controls Nc ̅̅̅̅ plus 0.16, and if Nc ̅̅̅̅ was less than 0.03, it was replaced by 0.03. For ELISA-IgM, the cut-off value was calculated as Nc ̅̅̅̅ multiply by 2.1, and if the Nc ̅̅̅̅ was less than 0.05, 0.05 was used as Nc ̅̅̅̅ . To calculate the relative antibody binding signal, the OD value of each sample was divided by the corresponding cut-off value of each assay. For CMIA-Ab, 50 μL of samples were mixed with 50 μL of paramagnetic microparticles coated with RBD, while for IgM-CMIA, 20 of μL sample was mixed with 50 μL of paramagnetic microparticles coated with anti-μ chain antibody and 50 μL sample dilution buffer. After incubation at 37 ℃ for 15 min, the mixtures were washed 2 times, and 100 μL of acridinium ester conjugated RBD were added, followed by incubation at 37 ℃ for 10 min. Then, the microparticles were washed for 4 times, and each 100 μL of pre-trigger solution (Hydrogen peroxide) and trigger solution (NaOH) were added and the relative light units (RLUs) was measured immediately. The cut-off value of CMIA-Ab was determined by RLUs of negative control plus (RLUs of positive control multiplied by 0.3), and that of CMIA-IgM was determined by RLUs of negative control plus (RLUs of positive control multiplied by 0.2).

The curves of the cumulative seroconversion rates for total antibody. (B) The curves of the cumulative seroconversion rates for IgM. (C) The curves of the cumulative seroconversion rates for IgG. The total antibody, IgM and IgG were detected by ELISA, and the curves were plotted according to Kaplan-Meier method. The serological status of patients was assigned to be negative before the time that the first sample was collected, even if the first sample tested positive. There was no significant difference in the cumulative seroconversion rate and median seroconversion time between critical and non-critical groups as analyzed by the Kaplan-Meier method.

(A) The curves of the cumulative seroconversion rates for total antibody. (B) The curves of the cumulative seroconversion rates for IgM. (C) The curves of the cumulative seroconversion rates for IgG. The total antibody, IgM and IgG were detected by ELISA, and the curves were plotted according to Kaplan-Meier method. The serological status of the patient was assigned to be negative before the time that the first sample was collected, even if the first sample tested positive. There was no significant difference in the cumulative seroconversion rate and median seroconversion time between critical and non-critical groups as analyzed by the Kaplan-Meier method.